Delenex closes series A round at CHF13.5 million
This article was originally published in Scrip
Delenex Therapeutics, the Swiss fragment company spun out of ESBATech in September 2009 when it was acquired by Alcon, has closed its series A round at CHF13.5 million (€10 million). The initial financing round involved leading venture capitalists SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. The funds will be used to finance the clinical development of programmes emerging from the company's single chain antibody fragment platform.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.